Trial Profile
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms OPTIENOX-PCI
- 08 Oct 2022 Status changed from recruiting to completed.
- 26 Mar 2021 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
- 26 Mar 2021 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2020.